https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43713 Wed 28 Sep 2022 10:22:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50282 Wed 13 Mar 2024 14:17:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22042 Wed 11 Apr 2018 09:42:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41886 PXS-5120A (12k), a potent, irreversible inhibitor that is >300-fold selective for LOXL2 over LOX. PXS-5120A also shows potent inhibition of LOXL3, an emerging therapeutic target for lung fibrosis. Key to the development of this compound was the utilization of a compound oxidation assay. PXS-5120A was optimized to show negligible substrate activity in vitro for related amine oxidase family members, leading to metabolic stability. PXS-5120A, in a pro-drug form (PXS-5129A, 12o), displayed anti-fibrotic activity in models of liver and lung fibrosis, thus confirming LOXL2 as an important target in diseases where collagen cross-linking is implicated.]]> Mon 15 Aug 2022 15:37:55 AEST ]]>